Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
Rhea-AI Summary
Aquestive Therapeutics (NASDAQ: AQST) will report fourth-quarter 2025 financial results after market close on Wednesday, March 4, 2026, and will provide recent business updates.
Management will host a conference call for investors on March 5, 2026 at 8:00 a.m. ET with a live webcast and a 30-day replay available on the company investor website.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
AQST showed a modest 0.51% gain with low volume, while notable peers were mixed: ESPR (-4.02%), ORGO (-1.75%), SIGA (-0.59%), AKBA (+1.68%), EOLS (-0.69%). Momentum scanner flagged other names (CRON, ETON) but not AQST, supporting a stock-specific reaction to the scheduling of its Q4 2025 results.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Conference participation | Neutral | +0.5% | Announcement of participation in Oppenheimer healthcare conference and webcast replay. |
| Feb 20 | Clinical data update | Positive | +0.4% | New Anaphylm clinical data presentations scheduled at 2026 AAAAI Annual Meeting. |
| Feb 18 | Management change | Positive | -1.3% | Appointment of Dr. Matthew Greenhawt as Chief Medical Officer to support NDA plans. |
| Feb 02 | Regulatory setback | Negative | +39.0% | FDA Complete Response Letter for Anaphylm focused on packaging and administration issues. |
| Jan 09 | Regulatory update | Negative | -37.0% | FDA identified deficiencies in Anaphylm NDA and company outlined cash of ~$120M. |
Recent AQST news has produced large, sometimes counterintuitive moves around Anaphylm regulatory updates, while conference and clinical data updates have seen modest, generally positive reactions.
Over the last few months, Aquestive has been driven mainly by Anaphylm regulatory developments. A Jan 9, 2026 update on FDA-identified NDA deficiencies and cash of about $120 million was followed by a steep negative reaction, while the Jan 30, 2026 Complete Response Letter on Anaphylm saw a sharp positive move of 38.98%. Subsequent events—including a new CMO appointment and upcoming clinical data presentations—have generated smaller moves. Today’s Q4 2025 earnings date notice fits into this ongoing regulatory and clinical narrative.
Market Pulse Summary
This announcement schedules Q4 2025 results for March 4, 2026 and an investor call on March 5. In context of recent FDA communications on Anaphylm and prior financing activity, investors may focus on updated cash levels, spending plans, and any regulatory or commercialization milestones discussed on the call. Monitoring how management frames Anaphylm timelines, broader pipeline priorities, and revenue concentration risks will be important when the full results and commentary are released.
AI-generated analysis. Not financial advice.
WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on recent developments in its business after market close on Wednesday, March 4, 2026.
Management will host a conference call for investors at 8:00 a.m. ET on Thursday, March 5, 2026. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on the Investors section of Aquestive’s website at: Fourth Quarter 2025 Earnings Call
Following the call, a replay of the webcast will be available on the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations. The webcast will be archived for 30 days.
About Aquestive Therapeutics
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates as both a developer of its own proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive's AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 (epinephrine prodrug) topical gel for various potential dermatological conditions, including alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward-Looking Statement
Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials, including relating to Anaphylm™ (dibutepinephrine) sublingual film, and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Investor Inquiries
Astr Partners
Brian Korb
Brian.korb@astrpartners.com
FAQ
When will Aquestive (AQST) release its fourth-quarter 2025 results and provide business updates?
What time and date is the Aquestive (AQST) investor conference call for Q4 2025?
How can investors access the Aquestive (AQST) earnings call and replay for Q4 2025?
Will Aquestive (AQST) provide a replay of the Q4 2025 earnings webcast, and for how long?
What topics will Aquestive (AQST) management cover on the March 5, 2026 earnings call?
